洞察
关于 AI 驱动生命科学探索的研究分析、行业视角与深度解析
精选
A closer look at a natural-product literature pilot in NYB.AI evaluated how NVIDIA Nemotron 3.5 Super VL could help verify compound records against their source publications.
洞察
For Vecura Biotech Insiders Spotlight #13, Chang Yong Zu shares all five generations, the controls as well as the leads, and what the contact data showed that the docking scores did not.
洞察
Vecura now runs Selenium, the retrosynthesis model from b12 Labs, as the final step of its discovery workflow, so a molecule you generate comes back with routes for making it. Here is what that looked like on a real run against NEK2.
洞察
How an output-driven perspective can help researchers select graph-based AI models for drug-target interaction research, with a closer look at DTIGN and LigoSPACE.
洞察
For Vecura Biotech Insiders Spotlight #12, Viet Nguyen Duc shares a structure-based screening campaign against HIV-1 protease built so that every threshold in it had to answer to a drug already known to work.
洞察
SuperWater, a generative AI framework developed to predict water molecule positions around biomolecular complexes, offers a new approach to this longstanding computational challenge.
洞察
For Vecura Biotech Insiders Spotlight #11, Ethan Lee shares a nine step campaign logged exactly as it ran, including the gate that failed every single design and the comparison that only existed because three candidates went forward instead of one.
洞察
For Biotech Insiders #10, Paolo Reyes shares a campaign that draws an unusually sharp line between what a generative docking model can be trusted with and what it can't, not because the model got confused, but because the two tasks are geometrically different problems wearing the same name.
洞察
For Vecura Biotech Insiders Spotlight #09, Kerem brought us a campaign that passed four straight stages of computational scrutiny and stalled on the fifth, the one that decides whether anyone could ever hold the molecule in their hand.
洞察
Hepatocellular carcinoma (HCC) is the predominant primary liver cancer and a major cause of cancer-related mortality worldwide. Despite advances in current therapies, advanced HCC remains difficult to treat, highlighting the need for new therapeutic targets.
洞察
For Biotech Insiders #08, Goh brought us a campaign that did not work, and a reasonable person reading the metrics at stage three would have called it finished. That is exactly why we asked to publish it
洞察
In this seventh edition of Vecura Biotech Insiders, we highlight a workflow shared with the Vecura team by Azlan Firdaus Iskandar: a constrained generative design campaign against amoxicillin's beta-lactam core, and what it took to stop the highest-scoring edit from being the one that breaks the drug.
